NASDAQ:DNLI Denali Therapeutics (DNLI) Stock Price, News & Analysis $18.08 -0.66 (-3.52%) Closing price 04:00 PM EasternExtended Trading$18.09 +0.01 (+0.06%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Denali Therapeutics Stock (NASDAQ:DNLI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Denali Therapeutics alerts:Sign Up Key Stats Today's Range$18.08▼$18.8650-Day Range$17.61▼$22.2852-Week Range$15.34▼$27.30Volume1.15 million shsAverage Volume1.72 million shsMarket Capitalization$2.90 billionP/E RatioN/ADividend YieldN/APrice Target$35.71Consensus RatingModerate Buy Company Overview Denali Therapeutics is a biotechnology company focused on developing medicines for neurodegenerative diseases and other disorders involving the nervous system. Founded in 2015, the company is headquartered in South San Francisco, California. Its research and development programs target conditions including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and lysosomal storage disorders. Denali’s portfolio includes investigational drug candidates that aim to address underlying disease processes, as well as its TransportVehicle platform, designed to help therapeutic molecules cross the blood-brain barrier. Denali was co-founded by Ryan Watts, who serves as the company’s chief executive officer. Its medicines remain in development, and the company’s work includes research and clinical testing of potential treatments for patients with neurological conditions.AI Generated. May Contain Errors. Read More Denali Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreDNLI MarketRank™: 3.76442499005 of 5 starsDenali Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 142nd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingDenali Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 1 strong buy rating, 13 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialDenali Therapeutics has a consensus price target of $35.71, representing about 95.0% upside from its current price of $18.32.Amount of Analyst CoverageDenali Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Denali Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Denali Therapeutics are expected to grow in the coming year, from ($2.62) to ($2.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Denali Therapeutics is -10.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Denali Therapeutics is -10.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDenali Therapeutics has a P/B Ratio of 2.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.15% of the float of Denali Therapeutics has been sold short.Short Interest Ratio / Days to CoverDenali Therapeutics has a short interest ratio ("days to cover") of 9.91.Change versus previous monthShort interest in Denali Therapeutics has recently decreased by 5.04%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDenali Therapeutics does not currently pay a dividend.Dividend GrowthDenali Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.64 News SentimentDenali Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Denali Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for DNLI on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat Follows6 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $64,882.00 in company stock.Percentage Held by Insiders9.70% of the stock of Denali Therapeutics is held by insiders.Percentage Held by Institutions92.92% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Denali Therapeutics' insider trading history. Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DNLI Stock News HeadlinesDenali Therapeutics Inc. (NASDAQ:DNLI) Stock Has Consensus Target Price of $35.71November 16 at 2:28 AM | americanbankingnews.comDenali Therapeutics (NASDAQ:DNLI) Research Coverage Started at Wells Fargo & CompanyNovember 16 at 1:36 AM | americanbankingnews.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 16 at 1:00 AM | Weiss Ratings (Ad)Transcript : Denali Therapeutics Inc. Presents at Stifel 2026 Healthcare Conference 2026, Nov-11-2026 09:20 AMNovember 14 at 8:11 AM | marketscreener.comMDenali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptNovember 13 at 11:00 PM | seekingalpha.comDenali: Commercial Biotech, Scaled The Brain's Wall Once, Second Summit In Sight (Initiating Buy)November 13 at 8:27 AM | seekingalpha.comGuggenheim reaffirms top pick in Biotech after Q3 resultsNovember 9, 2026 | uk.finance.yahoo.comB. Riley Securities Keeps Their Buy Rating on Denali Therapeutics (DNLI)November 9, 2026 | theglobeandmail.comSee More Headlines DNLI Stock Analysis - Frequently Asked Questions How have DNLI shares performed this year? Denali Therapeutics' stock was trading at $16.51 on January 1st, 2026. Since then, DNLI stock has increased by 10.9% and is now trading at $18.3160. How were Denali Therapeutics' earnings last quarter? Denali Therapeutics Inc. (NASDAQ:DNLI) released its quarterly earnings results on Tuesday, November, 3rd. The company reported $0.37 earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.64. The firm earned $17.78 million during the quarter, compared to analyst estimates of $12.67 million. Read the conference call transcript. When did Denali Therapeutics IPO? Denali Therapeutics (DNLI) raised $250 million in an initial public offering on Friday, December 8th 2017. The company issued 13,888,888 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager. Who are Denali Therapeutics' major shareholders? Top institutional shareholders of Denali Therapeutics include State Street Corp (4.17%), Fisher Asset Management LLC (1.54%), Pictet Asset Management Holding SA (0.99%) and Aberdeen Group plc (0.95%). Insiders that own company stock include Ryan J Watts, Alexander O Schuth, Carole Ho, Vicki L Sato and Jennifer E Cook. View institutional ownership trends. How do I buy shares of Denali Therapeutics? Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Denali Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Denali Therapeutics investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Intel (INTC), Marvell Technology (MRVL), Advanced Micro Devices (AMD), Tesla (TSLA) and Boston Scientific (BSX). Company Calendar Last Earnings11/03/2026Today11/16/2026UBS Global Biopharma Conference 202611/17/2026Jefferies Global Healthcare Conference11/18/20269th Annual Evercore ISI HealthCONx Conference12/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 4 days ago, DNLI's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DNLI CIK1714899 Webwww.denalitherapeutics.com Phone(650) 866-8547FaxN/AEmployees507Year Founded2015Price Target and Rating Average Price Target for Denali Therapeutics$35.71 High Price Target$42.00 Low Price Target$24.00 Potential Upside/Downside+97.5%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($1.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$512.54 million Net MarginsN/A Pretax Margin-1,470.03% Return on Equity-54.94% Return on Assets-42.15% Debt Debt-to-Equity Ratio0.01 Current Ratio6.21 Quick Ratio5.94 Sales & Book Value Annual Sales$330.53 million Price / Sales8.77 Cash FlowN/A Price / Cash FlowN/A Book Value$6.91 per share Price / Book2.62Miscellaneous Outstanding Shares160,290,000Free Float144,743,000Market Cap$2.90 billion OptionableOptionable Beta1.08 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:DNLI) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.